Jun 29, 2017
FDA Approves VNS Therapy Treatment for Drug-Resistant Epilepsy in Children as Young as Four Years Old
Jun 27, 2017
LivaNova to Host Conference Call for Second Quarter 2017 Results
Jun 21, 2017
VNS Therapy Receives FDA Approval for Expanded MRI Labeling
Jun 12, 2017
LivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel
May 16, 2017
LivaNova Announces Thad Huston as Chief Financial Officer